ScinoPharm Taiwan Ltd. (Taiwan, China)

Founded in 1997, with initial on-site operations beginning in November 1999, ScinoPharm Taiwan Ltd. offers a wide array of process R&D services and API manufacturing capabilities designed to satisfy customers' exact requirements and facilitate their rapid market introductions. ScinoPharm specializes in process R&D and the production of CGMP Active Pharmaceutical Ingredients (APIs). The company mainly provides anastrozole, galantamine hydrobromide, azacitidine, gemcitabine hydrochloride, benazepril hydrochloride, granisetron hydrochloride, bimatoprost, irinotecan hydrochloride, bivalirudin, letrozole, capecitabine, omeprazole, cladribine, ondansetron hydrochloride, dantrolene sodium, oxandrolone, oecitabine, paclitaxel, desmopressin acetate, pemetrexed 2Na and docetaxel anhydrous, among others. It distributes its products in domestic markets, and to overseas markets, including the rest of Asia, the Americas, Australia and Europe. The company also provides pharmaceutical industry technical services. To address the demands of both multinational companies and local formulation companies, ScinoPharm is constructing a new GMP plant in Changshu, Jiangsu Province. The plant, slated to be fully operational by 2011, will be used for the production of GMP grade pharmaceutical intermediates initially, and later be equipped to handle API production.